As senescent cells are progressively becoming therapeutically targetable due to the emerging field of senolytics, strategies eliminating senescent cells may be additionally implemented for complete eradication of LKB1-deficient tumours following treatment with metabolic stressors. This evidence concerns the gene STK11 and neoplasm.